Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bicalutamide in AR+ ER-/PR- metastatic breast cancer
NCT00468715Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Mar 2007
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of bicalutamide in breast cancer, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: 6-month Response Rate (Complete Response, Partial Response, and Stable Disease). Started Mar 2007; status: completed.
02
Drugs
bicalutamide
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00468715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00468715.